Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

State Rx Rebate Requirements For Non-Medicaid Populations Endorsed By Sen. Kerry

This article was originally published in The Pink Sheet Daily

Executive Summary

A Kerry Administration would support states’ use of Medicaid prior authorization lists to get non-Medicaid rebates. The Democratic Presidential candidate renews his call for reimportation from Canada at a campaign stop focused on drug costs.

You may also be interested in...



Democratic Candidate Kerry On Rx Pricing: Canada Can Do Better

Acceptance speech includes call for reimportation and repeal of "non-interference" clause under Medicare Rx. Kerry also offers hopeful vision for potential of biomedical research.

Michigan Rx Rebate Requirement For Non-Medicaid Programs Upheld By Appeals Court

D.C. federal appeals court affirms the lower court's rejection of PhRMA's arguments, citing the Supreme Court's decision in the group's case against Maine's prior authorization program. The court ruled that a link between Medicaid and non-Medicaid prices does not go against the "best interest" of Medicaid beneficiaries.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.

Topics

UsernamePublicRestriction

Register

PS060272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel